Development of model for identifying homologous recombination deficiency (HRD) status of ovarian cancer with deep learning on whole slide images

被引:0
|
作者
Zhang, Ke [1 ]
Qiu, Youhui [2 ]
Feng, Songwei [1 ]
Yin, Han [1 ]
Liu, Qi [1 ]
Zhu, Yuxin [1 ]
Cui, Haoyu [2 ]
Wei, Xiaoying [3 ]
Wang, Guoqing [3 ]
Wang, Xiangxue [2 ]
Shen, Yang [1 ]
机构
[1] Southeast Univ, Zhongda Hosp, Sch Med, Dept Obstet & Gynaecol, Nanjing 210009, Peoples R China
[2] Nanjing Univ Informat Sci & Technol, Inst AI Med, Sch Artificial Intelligence, Nanjing, Peoples R China
[3] Southeast Univ, Zhongda Hosp, Sch Med, Dept Pathol, Nanjing, Peoples R China
关键词
Deep learning; Whole slide images (WSIs); Homologous recombination deficiency (HRD); Ovarian cancer; FEATURES;
D O I
10.1186/s12967-025-06234-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BackgroundHomologous recombination deficiency (HRD) refers to the dysfunction of homologous recombination repair (HRR) at the cellular level. The assessment of HRD status has the important significance for the formulation of treatment plans, efficacy evaluation, and prognosis prediction of patients with ovarian cancer.ObjectivesThis study aimed to construct a deep learning-based classifier for identifying tumor regions from whole slide images (WSIs) and stratify the HRD status of patients with ovarian cancer (OC).MethodsThe deep learning models were trained on 205 H&E-stained sections which contained 205 ovarian cancer patients, 64 were found to have HRD status while 141 had homologous recombination proficiency (HRP) status from two institutions Memorial Sloan Kettering Cancer Center (MSKCC) and Zhongda Hospital, Southeast University. The framework includes tumor regions identification by UNet + + and subtypes of ovarian cancer classifier construction. Referring to the EasyEnsemble, we classified the HRP patients into three distributed subsets. These three subsets of HRP patients were combined with the HRD patients to establish three new training groups for subsequent model construction. The three models were integrated into a single model named Ensemble Model.ResultsThe UNet + + algorithm segmented tumor regions with 81.8% accuracy, 85.9% recall, 83.8% dice score and 68.3% IoU. The AUC of the Ensemble Model was 0.769 (Precision = 0.800, Recall = 0.727, F1-score = 0.762) in the study. The most discriminative features between HRD and HRP comprised S_mean_dln_obtuse_ratio, S_mean_dln_acute_ratio and mean_Graph_T-S_Betweenness_normed.ConclusionsThe models we constructed enables accurate discrimination between tumor and non-tumor tissues in ovarian cancer as well as the prediction of HRD status for patients with ovarian cancer.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Characterization of epithelial ovarian cancer based on multigene tumor testing and homologous recombination deficiency (HRD) testing (COMBO)
    Spenard, Elisabeth
    Care, Melanie
    McCuaig, Jeanna
    Clarke, Blaise
    Kim, Raymond
    Ferguson, Sarah
    Ranich, Laura
    Stockley, Tracy
    Bernardini, Marcus
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S162 - S162
  • [22] Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
    Incorvaia, L.
    Russo, T. D. Bazan
    Perez, A.
    Brando, C.
    Ferraro, P.
    Simone, A.
    Bono, M.
    Castellana, L.
    Insalaco, L.
    Contino, S.
    Gottardo, A.
    Gristina, V.
    Galvano, A.
    Corsini, L. R.
    Fanale, D.
    Badalamenti, G.
    Russo, A.
    Bazan, V.
    ANNALS OF ONCOLOGY, 2024, 35 : S955 - S955
  • [23] Identifying and Counting Avian Blood Cells in Whole Slide Images via Deep Learning
    Vogelbacher, Markus
    Strehmann, Finja
    Bellafkir, Hicham
    Muehling, Markus
    Korfhage, Nikolaus
    Schneider, Daniel
    Roesner, Sascha
    Schabo, Dana G.
    Farwig, Nina
    Freisleben, Bernd
    BIRDS, 2024, 5 (01): : 48 - 66
  • [24] ctDNA from ascites as an alternative to tumor sampling for HRD (homologous recombination deficiency) testing in ovarian cancer (OC).
    Leary, Alexandra
    el Hazzaz, Reda
    Le Formal, Audrey
    Lecerf, Elodie
    Brizais, Chloe
    Blameble, Emeline Colomba
    Gouy, Sebastien
    Maulard, Amandine
    Boursin, Yannick
    Pautier, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction
    Chiang, Ying-Cheng
    Lin, Po-Han
    Cheng, Wen-Fang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer: application model for practice
    Du, Jinsui
    Zhu, Lizhe
    Duan, Chenglong
    Ma, Nan
    Zhou, Yudong
    Li, Danni
    Zhang, Jianing
    Zhang, Jiaqi
    Wang, Yalong
    Liu, Xi
    Ren, Yu
    Wang, Bin
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2025, 30 (01)
  • [27] Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer
    Chiang, Ying-Cheng
    Huang, Hsien-Neng
    Kuo, Kuan-Ting
    Hwu, Wuh-Liang
    Lin, Po-Han
    JOURNAL OF OVARIAN RESEARCH, 2025, 18 (01)
  • [28] Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC).
    Patel, Jai Narendra
    Sehouli, Jahid
    Timms, Kirsten
    Solimeno, Cara
    Reid, Julia E.
    Lanchbury, Jerry S.
    Braicu, Ioana
    Darb-Esfahani, Silvia
    Ganapathi, Mahrukh
    Ganapathi, Ram N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
    Fiegl, H.
    Reimer, D.
    Schnaiter, S.
    Leitner, K.
    Wimmer, K.
    Schamschula, E.
    Steger, K.
    Marth, C.
    Zeimet, A. G.
    ANNALS OF ONCOLOGY, 2023, 34 : S527 - S527
  • [30] An optimized homologous recombination deficiency (HRD) algorithm ASGAD for predicting PARP inhibitor response in ovarian cancer patient.
    Jiao, Yang
    Chen, Dong Ju
    Liu, Bo
    Meng, Pei
    Sun, Lei
    Cai, Yu Hang
    Shi, Tai Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)